We studied the effect of complete response (CR) among 126 consecutive patients who underwent stem cell transplantation (SCT) for myeloma. The CR rate with SCT was 33%. Median overall survival (OS) from diagnosis of myeloma was 56 months. OS following SCT was 22 months. Progression-free survival (PFS) was 12 months. OS was not different between patients who achieved CR and those who did not, median survival 25 vs 24 months, P = 0.5. Corresponding median times for PFS were 15 and 11 months, P = 0.2. The plasma cell labeling index (PCLI) was high (у1%) in 36% (high risk group) and was associated with poor OS and PFS (P Ͻ 0.001). Achieving CR did not influence OS or PFS in either the high or the low risk group. In contrast, OS and PFS were significantly influenced by high PCLI both in patients who achieved CR and those who did not. OS was poor (Ͻ30 months) in high risk patients regardless of CR status and in low risk patients who did not achieve CR, compared to low risk patients achieving CR (57 months), making them candidates for novel posttransplant treatment options. Outcome following SCT is dependent more on biological variables such as the PCLI than on CR status. Bone Marrow Transplantation (2000) 26, 979-983. Keywords: multiple myeloma; complete response; prognosis; transplantation Multiple myeloma is a clonal plasma cell proliferative disorder that is characterized by the presence of a monoclonal (M) protein in the serum or urine, lytic bony lesions, renal failure, anemia and hypercalcemia. It accounts for 1% of all cancers, and 10% of all hematologic malignancies.
Multiple myeloma is a clonal plasma cell proliferative disorder that is characterized by the presence of a monoclonal (M) protein in the serum or urine, lytic bony lesions, renal failure, anemia and hypercalcemia. It accounts for 1% of all cancers, and 10% of all hematologic malignancies. 1, 2 In 2000, approximately 13 700 new cases of myeloma will be diagnosed and over 11 000 will die of the disease in the United States. 2 Therapy for myeloma is not curative. The overall response rate with standard melphalan and prednisone therapy is approximately 50% and the complete response (CR) rate is less than 10%. 3, 4 Combination chemotherapy leads to superior response rates (60-70%), but is without survival benefit. 3, 5, 6 High-dose therapy followed by autologous blood cell transplantation results in response rates exceeding 75-90%, 4, 5 and CR rates in the range of 20-40%. 7, 8 A French randomized trial has demonstrated improved survival with autologous marrow transplantation compared to conventional chemotherapy, with 5 year survival rates of 52% and 12%, respectively. 7 Complete response is a major goal of transplantation, and there are ongoing efforts to improve the CR rate by employing more aggressive induction therapy or performing tandem transplantation, or both. 9 Studies are also ongoing to improve the duration of CR with novel posttransplant therapeutic strategies. However, it is not clear that improving the CR rate will necessarily translate to better survival, and approaches to improve CR are usually associated with greater toxicity. The Finnish Leukaemia study group found that, among conventionally treated patients, the degree of response (ie 25% vs 50% vs 90% or complete response) did not seem to affect survival. 10 Conversely, a recent study by the Eastern Cooperative Oncology Group (ECOG) found complete response to be an important favorable prognostic factor in patients treated with conventional-dose chemotherapy.
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There are several independent prognostic factors that determine survival in myeloma, 12 and it is likely that the effect of CR on survival is different between the high and low risk groups defined using these prognostic factors. This knowledge may allow better selection of patients for aggressive approaches to improve CR and survival. The purpose of this study was to determine the effect of CR on patients undergoing stem cell transplantation for myeloma, stratified into high and low risk groups based on known prognostic factors.
Patients and methods

Patients and data collection
One hundred and twenty-six patients underwent high-dose therapy and stem cell transplantation for refractory or relapsed myeloma at the Mayo Clinic between June 1989 and April 1999. Data from transplant patients are collected prospectively and entered into a comprehensive computerized database. Response to therapy, relapse and survival data are continuously updated. Information on prognostic factors including beta 2-microglobulin (␤-2M) (all patients), bone marrow plasma cell percentage (all patients), circulating plasma cells (124 patients), plasma cell labeling index (PCLI) (122 patients), cytogenetic analysis (120 patients), C-reactive protein (CRP) (109 patients), and lactate dehydrogenase (LDH) (108 patients), collected just prior to transplant were used for the purposes of this study.
Stem cells were harvested in most patients after initial chemotherapy with vincristine, doxorubicin and dexamethasone (VAD) chemotherapy. The conditioning regimen (high-dose therapy) consisted of melphalan 140 mg/m 2 and total body irradiation (TBI) (1200 cGy) in 101 patients. Eleven patients received melphalan, cyclophosphamide and TBI, and 11 others received melphalan 200 mg/m 2 . Three patients received other regimens. All patients had stem cells re-infused following high-dose therapy except for one patient (included in the analysis) who died of sepsis, 1 day prior to stem cell infusion.
No patients were lost to follow-up. All patients gave written informed consent for research bone marrow and blood samples and again prior to stem cell mobilization. Approval of the protocol by the Mayo Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
Response and survival
Complete response was defined as lack of detectable monoclonal (M) protein in serum and urine by immunoelectrophoresis and immunofixation. Since a bone marrow biopsy was not performed routinely to document CR, bone marrow plasma cells were not included in the definition of CR. Partial response was defined as reduction of serum M protein and 24 h urinary light chain excretion by at least 50% accompanied by a similar reduction of soft tissue plasmacytomas if present. Disease progression was defined as a 50% increase in the serum M protein or 24 h urinary M protein excretion over the lowest remission level. Increase in the size of existing lytic bony lesions or soft tissue plasmacytomas or appearance of new lytic bony lesions constituted progression. In complete responders, any detectable M protein by immunofixation also constituted progression. Survival was measured both from the date of transplant and from the date myeloma was initially diagnosed, to the date of death or last follow-up. Progression-free survival (PFS) was defined as time from transplant to disease progression or death.
Prognostic factors and risk groups
Bone marrow PCLI, cytogenetics and other laboratory parameters were assessed pretransplant. PCLI, a reflection of the proliferative activity, was performed using a slide-based immunofluorescence method on bone marrow samples as described elsewhere. 13 A PCLI of у1% was classified as high. For cytogenetic analysis, bone marrow specimens were processed by both direct and short-term culture techniques as described previously. 14, 15 Circulating plasma cells were estimated based on a similar method as described elsewhere. 16 Circulating plasma cells were defined as a poor prognostic factor when у3% of cytoplasmic immunoglobulinpositive cells were considered plasma cells by morphologic examination.
For this study, risk group stratification was based on PCLI, with the high risk group defined as patients with a high PCLI.
Statistical analysis
Survival analysis was done using the method described by Kaplan and Meier. 17 Differences between survival curves were tested for statistical significance using the two-tailed log rank test. The following prognostic factors for overall and PFS after transplantation were tested in a univariate analysis: age, sex, ␤-2M, LDH, CRP, PCLI, bone marrow plasma cell percentage, bone marrow cytogenetics and presence of circulating plasma cells. Factors that significantly predicted for survival in the univariate model were then studied in a multivariate analysis using Cox's proportional hazards model. 18 The chi-square and Fisher exact tests were used to compare differences in nominal variables; the rank-sum test was used for continuous variables.
Results
Eighty-two men and 44 women, ages 33-71 years (median, 55), were studied. Patient characteristics are listed in Table 1 . Ninety patients (71%) were transplanted for relapsed disease, 19 (15%) for primary refractory disease, and 17 (14%) were transplanted in the plateau phase. Seventy-two percent had failed two or more prior chemotherapeutic regimens.
Patients underwent transplantation 5-88 months (median, 20) after the initial diagnosis of myeloma.
Response and survival analysis
The overall response rate with stem cell transplantation was 97%, and the CR rate was 33%.
Sixty patients have died, including five who died of transplant-related complications. The median survival from the time myeloma was first diagnosed was 56 months. Median survival from the date of transplant was 22 months for the cohort; PFS was 12 months.
Univariate analysis
Univariate survival comparisons are shown in Table 2 for overall and PFS. Age, gender, time from initial diagnosis and response to prior chemotherapy were not predictive of survival or progression. Overall survival among complete responders was 24 months, and was not significantly different compared to patients failing to achieve a CR (19 months), P = 0.11. Corresponding median times for PFS were 19 and 9 months respectively, P = 0.04. Since CR is a time-dependent covariate, survival analysis was repeated using a landmark analysis at 100 days, thereby excluding patients who did not live long enough to achieve a CR. In this model, overall survival among patients who achieved a CR was similar to those who did not, median survival 25 vs 24 months, P = 0.5 (Table 3 ; Figure 1a ). Corresponding median times for PFS were 15 and 11 months respectively, P = 0.2 ( Figure 1b) . Achieving CR did not affect overall survival or PFS (using landmark analysis) in either the high or the low risk group. In contrast, OS and PFS were significantly influenced by high PCLI both in patients achieving CR and those who did not (Table 3) . Overall survival among low risk patients (PCLI Ͻ1) who achieved a CR was 57 months, and was superior to high risk patients (PCLI у1) who achieved a CR (23 months), low risk patients who failed to achieve a CR (29 months), and high risk patients who failed to achieve a CR (14 months), P = 0.003 (Figure 2a ). Corresponding values for PFS were 31, 12, 12, and 8 months, respectively, P Ͻ 0.001 (Figure 2b) . The results were similar when cytogenetic abnormalities were substituted for PCLI in determining risk group stratification, and defining the high risk group as patients with abnormal cytogenetics, P = 0.003 (overall survival) and 0.004 (PFS). Similar results were also obtained when the analysis was done without the landmark model, using all patients.
Multivariate analysis
On multivariate analysis, PCLI and circulating plasma cells were independent adverse prognostic factors (Table 4) . Abnormal cytogenetics was not an independent predictor of poor survival in a model that already included the PCLI.
Bone Marrow Transplantation Figure 2 Kaplan-Meier estimation of (a) overall survival, and (b) progression-free survival for patients undergoing autologous transplantation for myeloma, stratified according to risk and complete response status.
Table 4
Multivariate analysis for overall and progression-free survival
Prognostic factor Progression-free Overall survival survival (P value) (P value)
Plasma cell labeling index Ͻ0.001 Ͻ0.001 Circulating plasma cells 0.007 Ͻ0.001
Conversely, the PCLI did not add significant predictive value to a model that already contains cytogenetics for both overall survival and PFS. None of the other prognostic factors studied were significant in the multivariate model.
Discussion
Complete response rates in myeloma have improved substantially with stem cell transplantation. Improving CR rates is felt to be an important surrogate for the long-term goal of improving survival in myeloma. Studies done at the University of Arkansas in newly diagnosed myeloma clearly demonstrate incremental achievement of CR with each step of the total therapy program. 9 CR rates in their program increased from 5% with initial induction with VAD, to 26% following the first transplantation, and 38% with the second (tandem) transplantation. Duration of CR was significantly longer in the low risk group that lacked an unfavorable karyotype, suggesting that achieving a CR benefited the low risk group to a greater extent.
In this study we show that overall survival and PFS are dependent to a greater extent on biological variables such as PCLI and presence of chromosomal abnormalities than on achievement of a CR (Figures 1 and 2 ; Table 3 ). It appears that survival is poor in high risk patients regardless of CR status. Achieving a CR may be relatively more important among low risk patients and failure to achieve CR in this group led to poor survival similar to the high risk groups. However, this finding did not reach statistical significance in our study, probably as a result of the sample size.
When using a time-dependent covariate such as CR in survival analysis, erroneous results and conclusions can be made since patients who did not live long enough to achieve CR will be systematically excluded, weighting the analysis strongly in favor of those who achieved CR. 19 Thus, we used a landmark analysis in this study to remove this bias. The 100-day cut-off was chosen for the landmark analysis since this was the time at which most patients achieved CR.
The poor results with transplantation among high risk patients argue strongly in favor of additional post-transplant strategies designed to improve CR duration and survival. These patients should be considered candidates for immediate post-transplant adjuvant therapies. Similarly, low risk patients who fail to achieve a CR may be considered as treatment failures, making them candidates for novel posttransplant treatment strategies even before evidence of disease progression occurs. Results from randomized clinical trials may answer the question of whether aggressive approaches to improve CR rate such as tandem transplantation results in improved survival.
An important question is whether aggressive pretransplant chemotherapy is needed to improve long-term CR rate and survival. After multiple courses of induction therapy with VAD, high-dose cyclophosphamide, and EDAP (etoposide, dexamethasone, cytarabine, cisplatin), the CR rate in the Arkansas experience is only 15%. 9 It may be possible to achieve the same long-term results with simpler, less toxic induction regimens. An ongoing clinical trial at the Mayo Clinic is evaluating one such pretransplant induction regimen of thalidomide and high-dose dexamethasone. ECOG and other institutions are also planning similar trials.
Although survival after transplant in this study (median, 22 months after transplantation) appears lower than other reports, 5, 20, 21 this is clearly due to patient selection since we studied predominantly patients with relapsed or refractory myeloma. Thirty-six percent of patients in our study had a high (Ͼ1%) plasma cell labeling index, and 34% had abnormal cytogenetics, which are adverse prognostic factors (Table 1) . We also used a strategy of delayed transplantation, and the median time from initial diagnosis of myeloma to transplantation was 20 months. Survival after transplantation in our study is similar to a cohort of patients with advanced myeloma studied by Alexanian and colleagues. 22 Median survival measured from initial diagnosis of myeloma in the patients we studied was 56 months and is similar to results reported by other investigators. 23 Our study indicates that patients with high risk disease regardless of CR status, and low risk patients not achieving a CR do especially poorly following transplantation, and indicate a need to test innovative post-transplant strategies without waiting for relapse. Such approaches may include maintenance therapy with thalidomide or interleukin-12, dendritic cell vaccine strategies or mini-allogeneic transplantation for selected patients with a compatible donor. In addition, clinical trials may need to be designed with different therapeutic strategies and goals based on the baseline risk of the patient, in order to minimize toxicity and risk to low risk patients who may do well for prolonged periods regardless of the type of therapy received. The observation that survival is dependent to a greater extent on PCLI and other known prognostic factors than achievement of CR suggests that inherent tumor biology dictates outcome more than treatment intensity.
